Edition:
United Kingdom

Shire PLC (SHPG.OQ)

SHPG.OQ on NASDAQ Stock Exchange Global Select Market

169.72USD
13 Aug 2018
Change (% chg)

$0.00 (+0.00%)
Prev Close
$169.72
Open
--
Day's High
--
Day's Low
--
Volume
3,220
Avg. Vol
405,739
52-wk High
$177.51
52-wk Low
$123.73

Latest Key Developments (Source: Significant Developments)

Takeda Pharmaceutical Announces Statement Regarding US FTC Clearance
Tuesday, 10 Jul 2018 

July 10 (Reuters) - Takeda Pharmaceutical Company Ltd <4502.T>::STATEMENT REGARDING US FTC CLEARANCE.TAKEDA RECEIVES CLEARANCE FROM UNITED STATES FEDERAL TRADE COMMISSION FOR PROPOSED ACQUISITION OF SHIRE PLC.  Full Article

EMA Recommendations For June 2018
Friday, 29 Jun 2018 

June 29 (Reuters) - EU Medicines Agency::EMA RECOMMENDATIONS FOR JUNE 2018.EMA RECOMMENDS APPROVAL OF NOVARTIS GENE-BASED CELL THERAPY KYMRIAH.EMA RECOMMENDS APPROVAL OF BAXALTA' INNOVATIONS' DRUG FOR VON WILLEBRAND DISEASE VONICOG ALFA.EU MEDICINES AGENCY RECOMMENDS APPROVAL OF ULTRAGENYX DRUG FOR TREATMENT OF SLY SYNDROME.EU MEDICINES AGENCY RECOMMENDS APPROVAL OF GILEAD SCIENCES' CAR-T TREATMENT FOR ADVANCED NON-HODGKIN LYMPHOMA YESCARTA.  Full Article

Takeda Pharm CEO Weber Says Neuroscience Will Continue To Be A Core Area
Tuesday, 8 May 2018 

May 8 (Reuters) - Takeda Pharmaceutical Co Ltd <4502.T> Chief Executive Officer Christophe Weber::NEUROSCIENCE WILL CONTINUE TO BE A CORE AREA.JOBS COULD BE IMPACTED.  Full Article

GSK New R&D Head Barron Says Work To Do To Translate DPU Research Into Drugs
Wednesday, 25 Apr 2018 

April 25 (Reuters) - Glaxosmithkline ::NEW RESEARCH AND DEVELOPMENT HEAD BARRON SAYS WORK TO DO TO TRANSLATE RESEARCH AT DPU UNITS INTO DRUGS.  Full Article

GSK Expecting Shingrix Sales For Year To Be Above 400 Million Stg
Wednesday, 25 Apr 2018 

April 25 (Reuters) - GlaxoSmithKline ::CFO SAYS EXPECTING SHINGRIX SALES FOR YEAR TO BE AT THE SAME RATE AS IN Q1, OR 400 MILLION STG+ FOR 2018.  Full Article

Takeda Says Notes Statement By Shire Regarding Revised Proposal, Deadline Extension
Wednesday, 25 Apr 2018 

April 25 (Reuters) - Japan's Takeda Pharmaceutical Co Ltd <4502.T>::SAYS NOTES STATEMENT BY SHIRE PLC REGARDING REVISED PROPOSAL AND EXTENSION OF PUSU DEADLINE TO MAY 8, 2018.SAYS INTENDS TO MAINTAIN ITS WELL-ESTABLISHED DIVIDEND POLICY AND INVESTMENT GRADE CREDIT RATING.  Full Article

Shire announces Takeda's revised proposal of about 49 pounds per share
Wednesday, 25 Apr 2018 

April 24 (Reuters) - Shire Plc ::SHIRE ANNOUNCES REVISED PROPOSAL AND EXTENSION OF PUSU DEADLINE TO 8 MAY 2018.INDICATED TO TAKEDA WOULD BE WILLING TO RECOMMEND REVISED PROPOSAL TO SHAREHOLDERS SUBJECT TO SATISFACTORY RESOLUTION OF OTHER TERMS OF POSSIBLE OFFER.SATISFACTORY RESOLUTION OF OTHER TERMS OF POSSIBLE OFFER, INCLUDE COMPLETION OF RECIPROCAL DUE DILIGENCE BY SHIRE ON TAKEDA.REVISED PROPOSAL COMPRISES 0.839 NEW TAKEDA SHARES AND US$30.33 IN CASH FOR EACH SHIRE ORDINARY SHARE.REVISED PROPOSAL IMPLIES AN EQUIVALENT VALUE OF APPROXIMATELY £49 PER SHIRE ORDINARY SHARE.REVISED PROPOSAL COMPRISING OF £27.26 IN NEW TAKEDA SHARES; AND £21.75 IN CASH.REVISED PROPOSAL IS EQUIVALENT TO A VALUE OF APPROXIMATELY £46 BILLION FOR ENTIRE ISSUED AND TO BE ISSUED SHARE CAPITAL OF COMPANY.CO SHAREHOLDERS WOULD BE ENTITLED TO ANY DIVIDENDS ANNOUNCED BY SHIRE IN ORDINARY COURSE PRIOR TO COMPLETION OF POSSIBLE TRANSACTION.ON DEAL COMPLETION, SHIRE SHAREHOLDERS WOULD OWN APPROXIMATELY 50 PER CENT.OF THE ENLARGED TAKEDA AND THE NEW TAKEDA SHARES WILL BE LISTED IN JAPAN AND IN US THROUGH AN ADR PROGRAM.  Full Article

Takeda Confirms Made A Revised Proposal To Board Of Shire
Tuesday, 24 Apr 2018 

April 24 (Reuters) - Takeda Pharmaceutical Co Ltd <4502.T>::TAKEDA STATEMENT REGARDING SHIRE PLC.CONFIRMS THAT IT HAS MADE A REVISED PROPOSAL TO BOARD OF SHIRE .  Full Article

Shire Says Received Revised Proposal From Takeda On Possible Offer, Says Considering Its Position
Tuesday, 24 Apr 2018 

April 24 (Reuters) - Shire Plc ::SHIRE PLC: STATEMENT RE REVISED PROPOSAL.RECEIVED A REVISED PROPOSAL FROM TAKEDA REGARDING A POSSIBLE OFFER FOR COMPANY ON 24 APRIL 2018.BOARD IS CONSIDERING ITS POSITION.CAN BE NO CERTAINTY THAT ANY FIRM OFFER FOR COMPANY WILL BE MADE NOR AS TO TERMS ON WHICH ANY FIRM OFFER MIGHT BE MADE.  Full Article

Takeda Is Said To Near Preliminary Agreement To Buy Shire- Bloomberg
Tuesday, 24 Apr 2018 

April 24 (Reuters) - :TAKEDA IS SAID TO NEAR PRELIMINARY AGREEMENT TO BUY SHIRE - BLOOMBERG, CITING SOURCES.  Full Article

UPDATE 2-Amicus Therapeutics receives U.S. approval for Fabry disease drug

Aug 10 U.S. health regulators on Friday approved Amicus Therapeutics' Galafold, the first oral therapy to treat Fabry disease, a rare, sometimes fatal condition in which accumulation of fat damages several organs.